U.S. Markets closed

Teva Phase IIa Laquinimod trail results show positive data for Chron's

Teva Pharmaceutical Industries (TEVA) and Active Biotech (ACTI) announced the presentation of Phase IIa clinical data for investigational laquinimod in moderate to severe Crohn's disease, or CD. The findings demonstrated that treatment with orally administered laquinimod 0.5 mg/day resulted in a robust, early and consistent effect on remission and response rates in patients with moderate-to-severe CD versus placebo. The data were reported in an oral presentation at the 20th United European Gastroenterology, or UEG, Week conference